Buscar
Mostrando ítems 1-10 de 88
Early detection and quantification of mutations in the tyrosine kinase domain of chimerical BCR-ABL1 gene combining high-resolution melting analysis and mutant-allele specific quantitative polymerase chain reaction
(Taylor & Francis, 2013-03)
BCR–ABL1 point mutations are the most common cause of resistance in patients with chronic myeloid leukemia (CML) who fail or lose response to tyrosine kinase inhibitors. We have developed a rapid method to screen BCR–ABL1 ...
Detección de mutaciones en el dominio tirosina quinasa de BCR-ABL1 en pacientes colombianos con leucemia mieloide crónica LMC, resistentes al imatinibDetection of BCR-ABL1 Tyrosine Kinase Domain Mutations in Chronic Myeloid Leukaemia Patients with Imatinib Resistance in Colombia
(Instituto Nacional de CancerologíaGenética MédicaPrograma de Estudio y Control de Enfermedades Tropicales (PECET)Bogotá, Colombia, 2022)
Outcome of patients with chronic myeloid leukemia with T3151 BCR-ABL mutation
(Ferrata Storti Foundation, 2008-06-01)
Molecular measurement of BCR-ABL transcript variations in chronic myeloid leukemia patients in cytogenetic remission
(2010-11-18)
Abstract
Background
The monitoring of BCR-ABL transcript levels by real-time quantitative polymerase chain reaction (RT-qPCR) has become important to assess minimal residual ...
Molecular measurement of BCR-ABL transcript variations in chronic myeloid leukemia patients in cytogenetic remission
(2010-11)
Abstract
Background
The monitoring of BCR-ABL transcript levels by real-time quantitative polymerase chain reaction (RT-qPCR) has become important to assess minimal residual disease (MRD) and standard of care in the ...
Molecular measurement of BCR-ABL transcript variations in chronic myeloid leukemia patients in cytogenetic remission
(2010-11-18)
Abstract
Background
The monitoring of BCR-ABL transcript levels by real-time quantitative polymerase chain reaction (RT-qPCR) has become important to assess minimal residual ...
Specific assessment of BCR-ABL transcript overexpression and imatinib resistance in chronic myeloid leukemia patients
(Wiley Blackwell Publishing, Inc, 2009-04)
Imatinib mesylate has proven to be the most effective treatment in chronic myeloid leukemia. Nevertheless, imatinib resistance has raised concern and prompted interest in additional strategies to achieve disease eradication. ...
Repuesta al tratamiento en leucemia mieloide crónica refractaria mediante cuantificación del Gen BCR/ABL1
(Universidad de Guayaquil. Facultad de Ciencias Médicas. Escuela de Graduados, 2018)
Los pacientes con leucemia mieloide crónica reciben tratamiento con terapia dirigida de primera línea que son los inhibidores de tirosina cinasa de primera y segunda generación, pero pueden presentar refractariedad por ...